| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 17.12.1997 (9839
dage). |
Ingen historik.
| Branche | | Engroshandel med medicinalvarer og sygeplejeartikler (464610). |
| Sidst opdateret den 23.12.2007 og
angivet som gældende fra 01.01.2008 (6172
dage). |
| Historik | Start | Stop |
|---|
| Engroshandel med medicinalvarer og sygeplejeartikler (464610) | 01.01.2008 | |
| Engroshandel med medicinalvarer og sygeplejeartikler (514610) | 17.12.1997 | 31.12.2007 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 17.12.1997 (9839
dage). |
Ingen historik.
| Revisor | | KPMG P/S |
| Sidst opdateret den 06.01.2023 og
angivet som gældende fra 06.01.2023 (688
dage). |
| Kontaktoplysninger | | skriv.til@pharma.novartis.com. |
| Sidst opdateret den 23.09.2002 og
angivet som gældende fra 18.09.2002 (8103
dage). |
Ingen historik.
| Telefonnummer | | 39168400. |
| Sidst opdateret den 01.04.2000 og
angivet som gældende fra 23.01.2000 (9072
dage). |
Ingen historik.
| Navne | | NOVARTIS HEALTHCARE A/S. |
| Sidst opdateret den 22.11.2013 og
angivet som gældende fra 17.12.1997 (9839
dage). |
Ingen historik.
| Binavne | | CIBA-GEIGY A/S. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 17.12.1997 (9839
dage). |
| Historik | Start | Stop |
|---|
| CIBA-GEIGY A/S | 17.12.1997 | |
| SANDOZ A/S | 17.12.1997 | 11.10.2004 |
| Tegningsregel | | Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af en direktør i forening med et bestyrelsesmedlem. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 26.05.2010 (5296
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | 2 bestyrelsesmedlemmer + |
| 1 direktør + 1 bestyrelsesmedlem |
Ingen historik.
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:KPMG Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:25578198
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse C, stor virksomhed
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.
We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Novartis Healthcare A/S for the financial year 1 January – 31 December 2023 comprising income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.
In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2023 and of the results of the Company's operations for the financial year 1 January – 31 December 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the Management's review.
Our opinion on the financial statements døs not cover the Management's review, and we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration